Treatment Of Sickle Cell Disease

Handle URI:
http://hdl.handle.net/10754/595349
Title:
Treatment Of Sickle Cell Disease
Authors:
Essack, Magbubah ( 0000-0003-2709-5356 ) ; Bajic, Vladimir B. ( 0000-0001-5435-4750 ) ; Radovanovic, Aleksandar
Assignee:
King Abdullah University of Science and Technology
Abstract:
The present invention includes embodiments for treatment and/or prevention of sickle cell disease that employ Hydroxyfasudil or Isocoronarin D alone or either in conjunction with each other or an inducer of HbF production. The compounds may act synergistically, and the compounds employed circumvent the side effects seen with Hydroxyurea.
KAUST Department:
Computational Bioscience Research Center (CBRC); Computer, Electrical and Mathematical Sciences and Engineering (CEMSE) Division
Issue Date:
4-Dec-2014
Submitted date:
2014-06-23
Type:
Patent
Application Number:
US 20140356458 A1
Patent Status:
Published Application
Additional Links:
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220140356458%22.PGNR.&OS=DN/20140356458&RS=DN/20140356458; http://assignment.uspto.gov/#/search?adv=publNum:20140356458; http://www.google.com/patents/US20140356458; http://worldwide.espacenet.com/publicationDetails/biblio?CC=US&NR=2014356458A1&KC=A1&FT=D
Appears in Collections:
Patents; Computational Bioscience Research Center (CBRC); Computer, Electrical and Mathematical Sciences and Engineering (CEMSE) Division

Full metadata record

DC FieldValue Language
dc.contributor.authorEssack, Magbubahen
dc.contributor.authorBajic, Vladimir B.en
dc.contributor.authorRadovanovic, Aleksandaren
dc.date.accessioned2016-02-01T14:03:14Zen
dc.date.available2016-02-01T14:03:14Zen
dc.date.issued2014-12-04en
dc.date.submitted2014-06-23en
dc.identifier.urihttp://hdl.handle.net/10754/595349en
dc.description.abstractThe present invention includes embodiments for treatment and/or prevention of sickle cell disease that employ Hydroxyfasudil or Isocoronarin D alone or either in conjunction with each other or an inducer of HbF production. The compounds may act synergistically, and the compounds employed circumvent the side effects seen with Hydroxyurea.en
dc.relation.urlhttp://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220140356458%22.PGNR.&OS=DN/20140356458&RS=DN/20140356458en
dc.relation.urlhttp://assignment.uspto.gov/#/search?adv=publNum:20140356458en
dc.relation.urlhttp://www.google.com/patents/US20140356458en
dc.relation.urlhttp://worldwide.espacenet.com/publicationDetails/biblio?CC=US&NR=2014356458A1&KC=A1&FT=Den
dc.titleTreatment Of Sickle Cell Diseaseen
dc.typePatenten
dc.contributor.departmentComputational Bioscience Research Center (CBRC)en
dc.contributor.departmentComputer, Electrical and Mathematical Sciences and Engineering (CEMSE) Divisionen
dc.description.statusPublished Applicationen
dc.contributor.assigneeKing Abdullah University of Science and Technologyen
dc.description.countryUnited Statesen
dc.identifier.applicationnumberUS 20140356458 A1en
All Items in KAUST are protected by copyright, with all rights reserved, unless otherwise indicated.